Advancing Treatment of Disease with Innovative protein therapeutics and Technologies

Advancing therapeutics against anemia

Anemia is a condition resulting from low levels of red blood cells or hemoglobin, the body’s main oxygen-carrying components. It is a common side effect of chemotherapy, which is used to treat a variety of cancers. In the US alone, 13.4 million people were diagnosed with cancer in 20111, and about 5 in 10 who received chemotherapy developed anemia, depending on the type of cancer2.

Up until the 1990s blood transfusions were the mainstay of treatment of anemia3. Subsequently, erythropoietin-stimulating agents, such as epoetin alfa and darbepoetin alfa, became the main treatment option for some types of chemotherapy-induced anemia. However, there are serious safety concerns with this class of drugs which have led to a blackbox warning for these products4.

Scientists at Therapure Innovations have discovered a novel pathway (distinct from that of the erythropoietin pathway) involved in the activation of red blood cell precursors to help boost red blood cell production. We have developed a therapeutic monoclonal antibody that utilizes this pathway, which has advanced to phase 1 clinical trials for the treatment of anemia resulting from cancer chemotherapy.

REFERENCES

  1. http://seer.cancer.gov/statfacts/html/all.html. Accessed on March 2015.
  2. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer (Review). Cochrane Database Syst Rev 2012 Dec 12;12:CD003407.
  3. Henry DH. The evolving role of epoetin alfa in cancer therapy. The Oncologist 2004;9:97-107.
  4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cancer- and chemotherapy-induced anemia. Version 2.2014. Accessed August, 2013.

To learn more about our areas of research, platform technologies and pipeline products, or to explore opportunities to partner and/or collaborate with us to improve existing therapeutics, please contact us at innovations@therapurebio.com.